)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Kyowa Kirin
Kyowa Kirin (4151) investor relations material
Kyowa Kirin Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary9 Sep, 2026
Vision and strategic focus
Aims to deliver life-changing value by addressing unmet medical needs through innovative pharmaceuticals, focusing on patient-centric healthcare and operational excellence.
Emphasizes developing therapies for diseases lacking effective treatments, leveraging biotechnology and advanced drug delivery.
Seeks to build long-term trust with stakeholders through quality and innovation.
KHK4951 program overview
KHK4951 is being developed as an eye drop for maintenance therapy in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Targets a significant market with millions of global patients and a market size estimated at up to 1 trillion yen.
Aims to reduce the burden of frequent intravitreal injections by offering a non-invasive alternative.
Utilizes nanocrystallized tivozanib for efficient posterior eye delivery.
Clinical need and treatment concept
nAMD requires ongoing anti-VEGF intravitreal injections, which are burdensome for patients and healthcare providers.
KHK4951 proposes a maintenance strategy centered on daily eye drops, potentially reducing injection frequency and clinic visits.
Envisions self-managed daily therapy with professional intervention only as needed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kyowa Kirin
- Double-digit revenue and profit growth driven by global product demand and tech-licensing.4151
Q2 2026 - Revenue and profit soared on global growth, tech-licensing, and raised profit guidance.4151Q1 2026
- Record FY2025 revenue and profit, with FY2026 guided for higher sales but lower core margin.4151Q4 2025
- Kyowa Kirin takes full control of rocatinlimab, aiming for 2026 regulatory submissions and strong market growth.4151Investor presentation
- Revenue and profit fell on restructuring and price cuts, but pipeline and cash flow remain robust.4151Q3 2025
- Revenue and profit fell, but overseas growth and pipeline progress remained strong.4151Q2 2025
- Driving innovation in rare disease therapies, talent, and sustainability for global impact.4151Sustainability Meeting Presentation
- Global partnership accelerates ziftomenib's development with major financial and operational backing.4151Collaboration
- Strong overseas growth and Orchard acquisition drove revenue and profit gains.4151Q3 2024
Next Kyowa Kirin earnings date
Q3 20262 Nov, 2026
Kyowa Kirin
Next Kyowa Kirin earnings date
Q3 20262 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage